Browsing by Author "T. Rabi"
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
PublicationArticle Antitumor and cytotoxic investigation of amoora rohituka(Informa Healthcare, 1995) T. Rabi; R.C. GuptaAn ethyl acetate extract derived from the stem bark of Amoora rohituka exhibited antitumor activity on mice inoculated with Dalton's lymphoma ascites cells (DLA). Intraperitoneal administration of the extract at doses of 10 or 20 mg/kg/day prolonged the median survival time of the animals. It showed cytotoxicity against Dalton 's lymphoma ascites cells with a 50% inhibitory concentration (IC50) of 9 μg/ml, with no activity against Hep-2 cells from a tumor of the larynx. © 1995 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.PublicationArticle Antitumor and cytotoxic investigation of Amoora rohituka(Swets en Zeitlinger B.V., 1995) T. Rabi; R.C. GuptaAn ethyl acetate extract derived from the stern bark of Amoora rohituka exhibited antitumor activity on mice inoculated with Dalton's lymphoma ascites cells (DLA). Intraperitoneal administration of the extract at doses of 10 or 20 mg/kg/day prolonged the median survival time of the animals. It showed cytotoxicity against Dalton's lymphoma ascites cells with a 50% inhibitory concentration (IC50) of 9 μg/ml, with no activity against Hep-2 cells from a tumor of the larynx.PublicationArticle Antitumour activity of amooranin from Amoora rohituka stem bark(1996) T. RabiThe in vivo antitumour activity of amooranin was determined using N-nitrosomethyl urea-induced Sprague-Dawley rats mammary adenocarcinoma. Intraperitoneal administration of the compound at a dose of 10 or 20 mg/kg/day prolonged the mean survival time of the animals and significantly reduced tumour sizes.PublicationArticle Influence of Amoora rohituka on MCF-7 human mammary adenocarcinoma cells in vitro(1994) T. Rabi; R.C. Gupta; A.K. GulatiThe ethanol extract of Amoora rohituka stem bark showed Cytotoxicity against MCF-7 cell lines derived from human mammary adenocarcinoma with a 50% inhibitory concentration (IC50) of 30 μm/ml, but with no activity against HEp-2 from a tumour of the larynx.